TheraPanacea
Elie Mengin has a diverse work experience in research and development (R&D) roles. In 2012, they started their career as an R&D intern at TOTAL. Elie then moved on to HEVA HEOR in 2015, where they also worked as an R&D intern. In 2016, Elie joined Smart Impulse as an R&D intern before transitioning to Quarkslab later that year as an R&D engineer. At Quarkslab, they held the role until February 2021. Currently, Elie is working as an R&D engineer at TheraPanacea, a position they have held since June 2022.
Elie MENGEL's education history is as follows:
Elie MENGEL obtained a Doctorat in Applied Mathematics from the University of Paris I: Panthéon-Sorbonne, graduating in 2021.
Prior to this, Elie MENGEL completed a Master 2 in Random Modeling (formerly DEA Laure-Elie) in Applied Mathematics at Université Paris Cité, from 2015 to 2016.
In 2014 to 2015, Elie MENGEL pursued a Master 1 in Applied Mathematics in Economics and Finance at the University of Paris I: Panthéon-Sorbonne.
Elie MENGEL holds a Bachelor's Degree in Statistics, which was earned from the University of Vienna in 2013 to 2014.
Lastly, Elie MENGEL obtained a Licence in Applied Mathematics to Social Sciences from the University of Paris I: Panthéon-Sorbonne from 2011 to 2014.
This person is not in any offices
TheraPanacea
TheraPanacea is an innovative information technology company devoted to unlocking the power of AI-based solutions to drive innovation in healthcare. A spin-off of University Paris-Saclay, TheraPanacea works in close cooperation with the most prominent healthcare facilities to combine the power of its proprietary platforms with clinical domain-knowledge. Today, ART-Plan™, TheraPanacea dedicated suite for radio-oncology, is used by more than 60 cancer centres across Europe, Africa, Middle-East and the US and is helping to improve care for more than 60,000 patients every year. TheraPanacea also develops and operates the ART-Omics™ platform enabling pharmaceutical companies to accelerate clinical research by harnessing AI-based multi-modality biomarker discovery in clinical trials and their effective integration within the clinical workflow at scale in the form of certified medical devices.